Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Jun 29, 2023

PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures

SOUTH PLAINFIELD, N.J. , June 29, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the MIT-E trial of vatiquinone for the treatment of mitochondrial disease associated seizures (MDAS) failed to achieve its primary endpoint of reduction in observable motor seizures.

Jun 21, 2023

PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients

- D ose-dependent lowering of blood Huntingtin (HTT) protein levels at 12 weeks - - Favorable tolerability profile with no treatment-related serious adverse events or NfL spikes - - Conference call and webcast to be held June 21 st at 8:00 am EDT - SOUTH PLAINFIELD, N.J.

Jun 15, 2023

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , June 15, 2023 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on June 12, 2023 , the company approved non-statutory stock options to purchase an aggregate of 11,260 shares of its common stock and 17,660 restricted stock units ("RSUs"), each

Jun 02, 2023

PTC Therapeutics to Participate at Upcoming Investor Conferences

SOUTH PLAINFIELD, N.J. , June 2, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences: Jefferies Healthcare Conference Wednesday, June 7 at 12:30 p.m.

May 23, 2023

PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial

- Conference call and webcast to be held at 5:00 pm EDT - SOUTH PLAINFIELD, N.J. , May 23, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today reported topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia.

May 23, 2023

PTC Therapeutics Announces Strategic Pipeline Prioritization

- Preclinical and early research gene therapy programs discontinued - - Expected reductions of approximately 15% in residual 2023 OPEX - SOUTH PLAINFIELD, N.J. , May 23, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the discontinuation of preclinical and early research

May 17, 2023

PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients

- Highly statistically significant and clinically meaningful results - - 63% mean blood Phe reduction in primary analysis population (p

Apr 28, 2023

PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , April 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 24, 2023 , the company approved non-statutory stock options to purchase an aggregate of 10,770 shares of its common stock and 18,110 restricted stock units (RSUs), each

Apr 27, 2023

PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results

– First-quarter 2023 total revenue of $220 million , representing 48% year-over-year growth - – Readouts from four clinical studies expected in second quarter of 2023, three of which are registration-directed – SOUTH PLAINFIELD, N.J. , April 27, 2023 /PRNewswire/ -- PTC Therapeutics, Inc.

Apr 13, 2023

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results

SOUTH PLAINFIELD, N.J. , April 13, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, April 27 ,

Pagination

First page
Previous page
…
Page 5
Page 6
Current page 7
Page 8
Page 9
…
Next page
Last page